AbbVie Shares Dip 0.66% as Volume Surges 30% to Rank 54th in U.S. Trading

AbbVie (ABBV) closed 0.66% lower on Sept. 25, with a trading volume of $1.46 billion—up 30.76% from the previous day—ranking it 54th among U.S. stocks by volume. The biopharmaceutical giant’s shares underperformed amid mixed market conditions, despite increased liquidity in the session.

Recent regulatory scrutiny over its Humira biosimilar strategy and patent litigation risks weighed on investor sentiment. Analysts noted that ongoing legal challenges could impact the drug’s market exclusivity timeline, creating uncertainty ahead of critical court decisions. Short-term volatility remains elevated as stakeholders await clarity on potential revenue implications.

To back-test “buy the top 500 stocks by daily trading volume and hold them for one day,” the following parameters need confirmation: universe scope (e.g., all U.S. stocks or S&P 1500), ranking methodology (dollar volume vs. share volume), weighting rules (equal-weight vs. volume/share-cap weighted), execution timing (open-to-close vs. close-to-open), and risk controls (e.g., stop-loss limits). Once defined, a performance report will be generated to evaluate the strategy’s viability.